Dishman Carbogen Amcis swings to ₹66.7 Cr consolidated loss, revenue down 22% YoY
PAT -202.24% YoY · revenue -22.26% · margins compressing · miss vs street
₹507.37 Cr
-22.26% YoY
₹-66.73 Cr
-202.24% YoY
-13.06%
-22.9pp YoY
₹-4.26
Dishman Carbogen Amcis reported a consolidated net loss of ₹66.7 Cr for Q2 FY27, against a ₹65.3 Cr profit in Q2 FY26 and widening from a ₹57.9 Cr loss in Q1 FY27 — a second straight loss-making quarter that deepened 15% sequentially. Consolidated revenue fell 22.3% YoY and 25.1% QoQ to ₹507.4 Cr. The print missed our pre-result on-plan range of ₹680-720 Cr revenue and ₹45-55 Cr net profit by a wide margin — the business was expected to recover from Q1's deferral-driven loss and instead the shortfall widened, which is also a clear miss against Street consensus (Sell-rated, ₹165 target, ~5% downside from ₹173.7 pre-result) that had been pricing in execution risk on deferred CDMO work.
Q2 FY-2027 vs prior quarters
The margin bridge explains most of the damage: operating margin collapsed to 9.06% from 22.81% a year ago (roughly flat versus 8.87% in Q1 FY27), and net margin swung to -13.15% from +9.88%. Employee benefit expense (₹321.6 Cr) fell only 3.4% YoY even as revenue fell 22.3%, so the topline decline flowed almost straight through to the operating line. Measured against management's standing FY26 EBITDA margin guidance of 19.5-20% (reiterated on the February 2026 call), this quarter's 9.06% is a clear miss, and the longer-term target of restoring consolidated EBITDA margins to 25-26% within two years looks materially further away. No management press release accompanies this filing to explain the shortfall or reaffirm guidance.
The stock went into the print at ₹172.92, up 13% over the past month of trading.
Management reiterates its full-year FY26 EBITDA margin guidance of 19.5-20%, anticipating a stronger Q4 to offset a weaker Q3 product mix. The company projects a significant long-term ramp-up, targeting INR 500 crores in revenue from its India operations within 12-18 months, driven by a substantial INR 1,200 crore RFP
— This quarter: missed
Standalone (the India parent) posted a narrower ₹25.3 Cr loss on ₹83.6 Cr revenue — worse in percentage terms (NPM -30.2%) but small in absolute rupees, confirming that both the bulk of revenue and the bulk of the consolidated loss sit in the European/Swiss CDMO subsidiaries; readers comparing the two numbers should not read the smaller standalone loss as the fuller picture. The quarter also saw the company raise ₹53 Cr of fresh NCDs (₹38 Cr and ₹15 Cr tranches, on top of earlier ₹75 Cr and ₹15 Cr issuances) with consolidated debt-equity rising to 0.47x from 0.35x YoY, alongside late-October/early-November promoter family settlement and share-transfer disclosures.
W1
H2 EBITDA margin recovery toward management's FY26 guidance of 19.5-20% — Q2 printed just 9.06%, a wide gap to close.
W2
Debt trajectory: consolidated borrowings at ₹3,163.7 Cr (debt-equity 0.47x) after ₹53 Cr of fresh NCDs this quarter — watch for further issuance or stabilization.
W3
French facility breakeven guided for FY27 — a ₹66.7 Cr consolidated loss this quarter suggests that remains unmet so far.
Both statements clean/legible; no exceptional items in current quarter or year-ago quarter (the ₹1.69 Cr QIP write-off sits only in Q1 FY27), so raw YoY = adjusted YoY; no minority interest (wholly-owned group); standalone is India-parent-only and far smaller in scale than consolidated.
Recovery in Focus as CDMO Deferrals Unwind
Q1's ₹58 Cr loss turned on customer-ordered project delays, not structural margin collapse. Q2 results will test whether the company can stabilize as deferred work recognizes and whether the heavy debt raise is precautionary or indicative of deeper cash stress.
The Setup: Q1 Loss, H2 Reset
Q1 FY27 delivered a consolidated net loss of ₹57.9 Cr—a dramatic reversal from ₹23.4 Cr profit in Q1 FY26 and ₹21.7 Cr in Q4 FY26. The culprit: a customer-requested deferral of CDMO project deliverables worth roughly CHF 10 million, which pushed margin recognition into H2. Management called this timing, not deterioration. The question for Q2: does the trajectory recover, or was Q1 a symptom of stalling demand?
The consolidated EBITDA margin crashed to 8.9% YoY in Q1—painful, but if tied to project delays rather than pricing pressure or mix shift, should rebound in Q2 as deferred work recognizes. The Street is skeptical: consensus is Sell, with a ₹165 target price versus current ₹173.7—implying downside despite the company's own H2 reset narrative.
What to Expect
~₹680–₹720 Cr
H2 CDMO unwind + core pharma services; Q1 was ₹609 Cr
~10–12%
Recovery from Q1's 8.9%; management guided EBITDA margin similar to FY26 or slightly higher
~₹45–₹55 Cr
Path to profitability; depends on whether Q1 loss was one-quarter or ongoing trend
30–35% growth
Management FY27 guidance for India entity; strong if holding, but consolidated muted by legacy Western pharma services
A strong Q2 print would show: (1) revenue in the ₹700 Cr+ range, reflecting partial CDMO recovery; (2) margin back above 11% (consolidated EBITDA), indicating the Q1 dip was timing; (3) commentary affirming H2 execution and no further project deferrals; and (4) cash flow positive or near-flat despite the ₹128 Cr debt raise. A weak print would reveal revenue below ₹680 Cr (slipping trajectory), margin still compressed at <10%, guidance withdrawn or reduced, or renewed risk of customer churn or forex headwinds.
On Track?
Management guided to single-digit consolidated revenue growth for FY27 (a sharp deceleration from historical 15%+ growth) and EBITDA margin similar to FY26 or slightly higher. If Q1 was truly a timing event, Q2 should show the company clawing back toward that guide. If it remains depressed, the full-year delivery looks at risk, and the debt raise starts looking less like strategic capital and more like a lifeline. Watch whether management reiterates FY27 guidance unchanged, reduces it, or flags additional headwinds (forex, customer concentration, execution risk).
What the Street Says
Since Last Quarter
Debt capital raise: The company allotted ₹128 Cr in Senior, Secured, Rated, Listed Non-Convertible Debentures across three tranches (₹38 Cr in mid-Oct, ₹75 Cr in mid-Aug, ₹15 Cr in late Sept). This signals a pivot toward balance-sheet reinforcement amid growth ambitions—prudent, but the volume and pace flag cash burn concerns, especially in a loss quarter.
FDA inspection: The wholly-owned Swiss subsidiary (Carbogen Amcis AG, Vionnaz) cleared a US FDA inspection with zero observations in mid-September. A strong regulatory signal and de-risks the core CDMO platform.
Promoter activity: Family settlement and inter-se share transfers among Vyas family members (late October) signal internal restructuring. Promoter stake remains stable at ~59.3%. FII ownership declining slightly (6.86% in Q1 FY27 vs. 7.45% in Q4 FY26)—consistent with sentiment headwinds.
Management change: VP (Operations) Deepak Ram Chandra Mittal resigned effective August 27, 2026. Operational continuity risk, though not immediately critical.
What to Watch on Result Day
1 · CDMO project recognition & revenue
Does Q2 revenue recover to ₹700 Cr+? Are the deferred ₹10M+ CHF CDMO projects beginning to recognize? If revenue stays below ₹680 Cr or guides lower for H2, the H2-reset narrative collapses.
2 · Margin recovery & EBITDA guidance
Can EBITDA margin climb back above 11% consolidated? If still sub-10%, the company is signaling deeper structural issues (pricing, mix, or hidden cost pressures) beyond Q1 timing.
3 · Cash flow & debt trajectory
What is the cash position after ₹128 Cr debt raise? Is the company still burning? Management commentary on leverage ratios and capex intensity will clarify whether the raise is precautionary or reactive.
4 · Full-year guidance reaffirmation
Does management stick to single-digit consolidated growth and FY26-level EBITDA margin, or reduce? Any withdrawal or qualifier on H2 execution will signal risk reassessment.
Dishman Carbogen reports tomorrow amid a significant credibility test. Q1's ₹57.9 Cr loss and the subsequent ₹128 Cr debt raise have left the Street doubtful; the Sell consensus and ₹165 target reflect skepticism that the company will stabilize margins or execute H2 CDMO deferrals. Q2 must demonstrate that the Q1 dip was timing, not demand deterioration. Investors should focus on three things: (1) whether CDMO project deferrals are recognizing and revenue is recovering toward ₹700 Cr, (2) whether EBITDA margin bounces above 11% consolidated, confirming no structural margin erosion, and (3) whether management reaffirms full-year single-digit growth and comparable margins, or signals emerging headwinds. A strong print could arrest the decline in FII ownership and lift valuation; a weak one will validate the Sell thesis.